St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
- Fundraising
Acute Myeloid Leukemia (AML) Treatment
Also called: acute myelogenous leukemia, acute nonlymphocytic leukemia, AML
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. Bone marrow is a soft, sponge-like tissue in the center of many bones. It makes blood cells.
In AML, the bone marrow makes too many white blood cells that do not work correctly. Children with AML do not have enough healthy white blood cells. As a result, they cannot fight infections well. Children with AML can get very sick.
AML is the second most common form of childhood leukemia.
Learn more about acute myeloid leukemia on the Together by St. Jude™ online resource.
Treatment of acute myeloid leukemia
Chemotherapy is the main treatment for AML. It has 2 phases. Treatment takes about 6 months.
In some cases, children may have a stem cell (bone marrow) transplant. Another possible treatment is immunotherapy. In rare cases, children may have radiation therapy.
Treatment plans are based on several factors. These include the child’s age and white blood cell count before treatment.
Acute myeloid leukemia clinical trials
St. Jude offers clinical trials and cancer research studies for children, teens, and young adults for AML. Learn more about clinical research at St. Jude.
Recruiting
Study goal:
Find out the dose of revumenib, azacitidine and venetoclax that can be used to safely treat children, adolescents, and young adults with refractory or relapsed AML or ALAL
Age:
1–30 years old
Recruiting
Study goal:
To find out if adding venetoclax to standard chemotherapy leads to improved survival for children and young adults with relapsed AML.
Age:
29 days old to 21 years old
Recruiting
Study goal:
Study the side effects of using venetoclax and chemotherapy to treat children with AML; learn more about how this treatment works
Age:
Older than 28 days and younger than 22 years
Recruiting
Study goal:
The main purpose of this study is to find the highest dose of CD123-CAR T cells that is safe to give patients with AML. We also want to study the side effects of the treatment and learn how effective it is in fighting this type of cancer.
Age:
21 years old or younger
Recruiting
Study goal:
The main goal of this research study is to help us learn how to better treat pain and symptoms in children going through chemotherapy cancer treatment.
Age:
8 to 18 years old
Recruiting
Study goal:
The main goals of this study are to test the safety of venetoclax and selinexor and find the highest dose that is safe to give when combined with chemotherapy drugs. Researchers also want to find out about any side effects and learn how the treatment affects your body.
Age:
30 years or younger
Recruiting
Study goal:
1) To find out how many long-term survivors of leukemia have iron overload by using MRI testing. 2) To study how the number of red blood cell transfusions you received determines whether you have iron overload. 3) To explore how your age at the time of cancer therapy, the length of time from therapy, and gender affects whether you develop iron overload. 4) To find out if iron overload is causing problems with your organs.
Recruiting
Study goal:
This study will help us understand the effects of CPX-351 treatment in patients with MDS and AML.
Age:
1-22 years old
Recruiting
Study goal:
The purpose of this study is to find the highest dose of CD70+ CAR cells that is safe to give to patients with CD70+ blood cancers.
Age:
Up to 21 years old
Recruiting
Study goal:
To find the safest dose of imetelstat that can be given with fludarabine and cytarabine to stop the growth of cancer cells.
Age:
Between 12 months and 18 years old
Recruiting
Study goal:
To find the best dose of SNDX-5613 to use along with chemotherapy for young patients with KMT2A-R leukemia
Age:
1 month to 5 years old
Recruiting
Study goal:
To study the effects of talazoparib and chemotherapy for treating relapsed or refractory acute myeloid leukemia and acute myeloid leukemia of ambiguous lineage and to find the best dose for children and young adults.
Age:
Up to age 21
St. Jude provides the highest quality of care for patients with AML:
- We are consistently ranked among the best childhood cancer centers in the nation by US News & World Report.
- At St. Jude, we have created an environment where children can be children and families can be together.
- We lead more clinical trials for childhood cancer than any other hospital in the U.S.
- St. Jude is the only National Cancer Institute–designated Comprehensive Cancer Center just for children. A Comprehensive Cancer Center meets rigorous standards for research that develops new and better approaches to prevent, diagnose, and treat cancer.
- The nurse-to-patient ratio at St. Jude is about 1:3 in hematology and oncology and 1:1 in the Intensive Care Unit.
- Patients may be able to get expert, compassionate care and treatment closer to their homes through our St. Jude Affiliate clinics.
- St. Jude offers a dedicated team of specialists to meet the needs of children with cancer, including:
- Surgeons, doctors, and nurses who treat this cancer
- Doctors who specialize in radiation therapy and pathology (making a diagnosis by looking at tumor tissue under the microscope)
- Experts in diagnostic imaging and nuclear medicine
- Genetic counselors
- Clinical dietitians
- Child life specialists
- Psychologists
- Researchers and scientists
Seeking treatment at St. Jude
Patients accepted to St. Jude must have a disease we treat and must be referred by a physician or other qualified medical professional. We accept most patients based on their ability to enroll in an open clinical trial.
Contact the Physician / Patient Referral Office
Call: 1-888-226-4343 (toll-free) or 901-595-4055 (local) | Fax: 901-595-4011 | Email: referralinfo@stjude.org | 24-hour pager: 1-800-349-4334